The Legend Capital-backed sacral neuromodulation device developer floated in the middle of its range while upping the number of shares in the IPO.
Axonics Modulation Technologies, a US-based neuromodulation device developer backed by conglomerate Legend Holdings, will raise $120m today when it floats on the Nasdaq Global Select Market later today.
The company increased the number of shares in the initial public offering from 6.67 million to 8 million and priced them at the middle of the IPO’s $14 to $16 range. The underwriters have the option to buy an additional 1.2 million shares to increase its size to $138m.
Axonics has created…
